Immuneering reports Q2 net loss $14.4M; highlights 94% OS at 6 months in pancreatic cancer trial

Immuneering Corp

2025-Q2 EPS reported -$0.82

Net loss of $14.4M ($0.40/share) vs $14.1M ($0.47/share) in Q2 2024; cash $26.4M as of June 30.
94% overall survival at 6 months in Phase 2a of atebimetinib + mGnP in first-line pancreatic cancer (n=34); median OS not reached.
Third-line pancreatic cancer patient on atebimetinib monotherapy >18 months with confirmed partial response and 34% tumor reduction.
US composition of matter patent granted for atebimetinib provides exclusivity into 2042; pivotal trial expected in 2026.
Cash runway sufficient into 2026; End of Phase 2 meeting request submitted to FDA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.